Constellation Alpha Capital Corp

Constellation Alpha Capital — SPAC Merger (August 2018)

40 slides from Constellation Alpha Capital's SPAC merger presentation, Aug 3, 2018

  1. Slide 1: Constellation Alpha Capital Corp. Investor Presentation

    CONSTELLATION ALPHA CAPITAL CORP. Investor Presentation August 2018

  2. Slide 2: Disclaimer

    This presentation (the “Presentation”) is provided for informational purposes only and has been prepared to assist interested parties in making their own evaluation with respect to a potential business combination between Medall Healthcare Pvt . Ltd (“Target”) and Constellation Alpha Capital Corp .

  3. Slide 3: Management Biographies

    Rajiv Sarman Shukla, CEO • Conceived of Constellation Alpha Capital as India - focused healthcare roll - up platform • Former CEO of Pipavav Defence, publicly listed Indian company with ~4000 full - time and contract employees. Re - organized operatio ns to focus on services revenue in addition to c

  4. Slide 4: Executive Summary

    EXECUTIVE SUMMARY Constellation Alpha Capital Corp. • Conceived as an India - focused, healthcare roll - up platform • $143.75M IPO in June 2017 Biggest India focused IPO on Nasdaq • Rajiv Shukla to continue as CEO supported by existing Medall executive team • Expected to be only US - listed Indian

  5. Slide 5: Transaction Terms

    Pro Forma Capitalization (all figures in $M except number of shares & per share price) Transaction Terms Ownership Summary TRANSACTION TERMS 5 Illustrative share price $10.20 Number of shares outstanding (M) 20.03 Equity value $204.3 Existing Medall Net Debt 19.4 New Debt 30.0 Second Tranche Purchas

  6. Slide 6: Investment Rationale: Why India? Why Healthcare? Why Medall?

    INVESTMENT RATIONALE Why India? Why Healthcare? Why Diagnostics? Why Medall? India is the fastest growing major economy GDP Growth 2017 GDP, $Trillion 2015 2016 2017 2018E China 12.0 6.9% 6.7% 6.9% 6.5% India 2.6 8.2% 7.1% 6.6% 7.3% Brazil 2.1 (3.6%) (3.5%) 1.0% 2.4% Russia 1.5 (2.8%) (0.2%) 1.5% 1.

  7. Slide 7: Attractive Growth & Valuation Profile

    ATTRACTIVE GROWTH & VALUATION PROFILE Source: Bloomberg, July 31, 2018 Note: Detailed valuation table provided on slide 33 1. Median figures. Current year for Indian companies is from April 1 - March 31, 2019. Current year for US and EM peers is from Jan 1 - December 31, 2018. EBITDA reconciliation

  8. Slide 8: Potential Value Creation

    POTENTIAL VALUE CREATION 8 Illustrative Analysis: Potential Value Creation Normalized to $10 Share Price 1 Medium - term Longer - term $10 Potential Upside From Valuation Multiple Re - rating • 32% if current EV/EBITDA multiple is in line with average Indian Healthcare Services comps • 29% if curren

  9. Slide 9: Medall Overview

    MEDALL OVERVIEW

  10. Slide 10: Medall Overview

    MEDALL OVERVIEW Source: Medall data 1. Indian financial year is Apr 1 - Mar 31. All financials as per Indian GAAP. EBITDA reconciliation on slide 40 2. Other includes State of Maharashtra and Kerala 17% Revenue FY13 - 18 CAGR 1 ~25 million tests conducted p.a. 7,850+ Touch points ~570 Corporate Tie

  11. Slide 11: Medall History

    MEDALL HISTORY Source: Medall data, Public Press Reports 11 2009 2010 2011 2013 2015 2016 2017 Peepul Capital initiates company with acquisition of two radiology companies in Tamil Nadu State • Enter Karnataka State with acquisition • Enter Andhra Pradesh State with PPP • Cross million customer visi

  12. Slide 12: Market Leader in Pathology & Radiology

    MARKET LEADER IN PATHOLOGY & RADIOLOGY Status Listed Unlisted IPO planned Listed Unlisted Inception 1949 1996 1981 1996 2009 Ownership Family (58%) Public (42%) Subsidiary of Fortis hospital Family (63%) Carlyle (37%) Family (64%) Public (36%) Private Equity owned for 9 years Private Equity Investme

  13. Slide 13: Hub & Spoke Business Model

    HUB & SPOKE BUSINESS MODEL 13 Sample Analysis Franchise PPP Contracts Lab - to - Lab Sample Collection & Imaging Medall Spokes Company Owned 241 Franchise 258 Govt Contracts 1,423 Lab - to - Lab 5,928 Total Centers 7,850 186 Labs Hubs Spokes Doctors Walk - ins Hospitals Corporate Customers Online Re

  14. Slide 14: Financial Performance

    5% 8% 9% 10% 11% 14% 18% 26% FY13 FY14 FY15 FY16 FY17 FY18 FY19E FY20E FINANCIAL PERFORMANCE 1,610 2,056 2,351 2,940 3,340 3,544 3,898 4,820 FY13 FY14 FY15 FY16 FY17 FY18 FY19E FY20E Revenue, INR million EBITDA, INR million 304 451 556 711 823 986 1,090 1,310 FY13 FY14 FY15 FY16 FY17 FY18 FY19E FY20

  15. Slide 15: Investment Merits

    INVESTMENT MERITS

  16. Slide 16: Investment Merits

    16 Large, high growth market in the fastest growing major economy Differentiated business model positioned to extend market leadership India’s leading Apex lab network provides strong foundation for geographic expansion Acquisition strategy to consolidate fragmented industry Attractive entry valuati

  17. Slide 17: India: Fastest Growing Major Economy in 2018

    INDIA: FASTEST GROWING MAJOR ECONOMY IN 2018 17 Source: World Bank 1.5 2.1 2.6 2.6 2.6 3.7 4.9 12.0 19.4 0.7% 0.5% 0.9% 7.4% 3.1% 1.9% 0.4% 7.3% 2.6% (2.8%) (3.6%) 1.1% 8.2% 2.3% 1.7% 1.4% 6.9% 2.9% Rank 2017 GDP $Trillion 2014 2015 2016 2017 2018E India is projected to be 5 th largest economy in 20

  18. Slide 18: GDP Growth Driving Equity Performance

    GDP GROWTH DRIVING EQUITY PERFORMANCE 18 Market Price Performance 1 2014 2015 2016 2017 2018 USA S&P500 11.4% (0.7%) 9.5% 19.4% 5.3% Japan Nikkei 7.1% 9.1% 0.4% 19.1% (0.9%) UK FTSE (2.7%) (4.9%) 14.4% 7.6% 0.8% HK Hang Seng 1.3% (7.2%) 0.4% 36.0% (4.5%) India Nifty 31.4% (4.1%) 2.8% 28.6% 8.8% Sour

  19. Slide 19: GDP Growth Fueling Personal Consumption

    GDP GROWTH FUELING PERSONAL CONSUMPTION Source: Trading Economics, India Healthcare Roadmap 2025, Bain Consulting , “Indian Hospitals, Ready to Consolidate”, Spark Capital Note: High income – Annual income greater than INR 2M; Middle income – Annual income in range of INR 0.15 – 2 M; Low income – An

  20. Slide 20: Diagnostics in Sweet Spot of Healthcare Sector

    Economic Growth Expected to Drive India to Close Gap With Peers DIAGNOSTICS IN SWEET SPOT OF HEALTHCARE SECTOR 20 Source: WHO, Spark Capital, NHA Indicators, Global Health Expenditure Database 1 Indian Healthcare Sector is Expected to Grow 2x Faster Than GDP 45 98 397 2008 2014 2025 $bn Diagnostics

  21. Slide 21: Differentiated Business Model

    DIFFERENTIATED BUSINESS MODEL 21 2 • One - stop shop for patients • Integrated Radiology and Pathology business model better positions us to partner with hospitals • Higher barrier to entry than standalone pathology businesses • Significant market leadership position in South India • Strong brand na

  22. Slide 22: Integrated Pathology & Radiology Platform Provides Superior Customer Value

    INTEGRATED PATHOLOGY & RADIOLOGY PLATFORM PROVIDES SUPERIOR CUSTOMER VALUE 22 2 High barriers to entry due to expertise & capex requirements Radiology is a must for corporate tie - ups and wellness packages Increasing incidence of cardiac, neurological, osteopathic diseases and oncology Strengthen t

  23. Slide 23: Regional Leader with Strong Brand Recall

    REGIONAL LEADER WITH STRONG BRAND RECALL Source: Company filings, Medall estimates 1 Indian financial year is Apr 1 - Mar 31. All financials as per Indian GAAP 23 Medall Player 2 Player 3 Player 4 Player 5 FY17 1 Revenue Customer Touch Points Maharashtra Company Managed 5 Franchisee Managed 0 Lab -

  24. Slide 24: Deep Experience in PPPs Opens Growth Avenues

    DEEP EXPERIENCE IN PPPs OPENS GROWTH AVENUES • 8 - year track record in PPPs. • PPP contracts in 3 States: Andhra Pradesh, Karnataka, Jharkhand Source: World Bank, Medall data Medall Has Deepest Experience with PPPs in Indian Healthcare 24 2 17.9% 4.7% 8.0% 1.3% USA India Total HC Spending Govt Spen

  25. Slide 25: Margin Expansion with Increasing Scale

    MARGIN EXPANSION WITH INCREASING SCALE Source: Medall data 1 Indian financial year is Apr 1 - Mar 31. All financials as per Indian GAAP. EBITDA reconciliation on slide 40 Revenue & EBITDA Margins Since Inception FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 11x 2x 2x EBITDA 4% 8% 9% 19% 22% 24% 24% 2

  26. Slide 26: Industry-Leading Apex Lab Network Provides Platform for Growth

    Total Labs Apex Labs INDUSTRY - LEADING APEX LAB NETWORK PROVIDES PLATFORM FOR GROWTH IN COLLECTION CENTERS Source: Medall data, Public data 1 1 4 26 7 189 368 186 26 4 • Hub capacity is principal bottleneck for sample processing • Industry leading hub capacity provides growth springboard Scalabilit

  27. Slide 27: Proven Record of Growth in Collection Centers Using Multiple Formats

    57 186 FY15 FY18 148 7,850 FY15 FY18 PROVEN RECORD OF GROWTH IN COLLECTION CENTERS USING MULTIPLE FORMATS 27 53x 3x Number of Customer Touch Points* Number of Labs Source: Medall data * No acquisitions conducted between FY15 - 18 4 Company Owned Pathology Radiology Centers Lab - to - Lab Franchisee

  28. Slide 28: Geographic Expansion: Wider & Deeper Footprint

    • Penetrate regions with limited coverage by other National Diagnostics Chains • Acquire Regional Leaders • Public - Private Partnerships at the State level Enter New Markets 3x Deeper Coverage Of Existing Markets in 5 Years GEOGRAPHIC EXPANSION: WIDER & DEEPER FOOTPRINT Source: Medall data 28 4 FY1

  29. Slide 29: Indian Diagnostics Industry Ripe for Consolidation

    INDIAN DIAGNOSTICS INDUSTRY RIPE FOR CONSOLIDATION 29 Source: Goldman Sachs Indian Healthcare report 5 44% 56% Indian Diagnostics Sector is Highly Fragmented 6% 94% Quest & LabCorp Top 2 USA India Top 5 Small chains Singleton labs 2015 2020E Source: Medall data Market Leaders Expected To Drive Conso

  30. Slide 30: US Diagnostics Industry Acquisitions Timeline

    2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Pathway Diagnostics • OralDNA Labs • Vasogen • Caritas Medical Labs Genomic Vision Societe Anonyme • Athena Diagnostics ($740M) • Celera ($657M) • AHS S.E.D Medical Labs ($51M) • OralDNA Labs • UMass Memorial Medical Center 1 • Dignity Health 2 • Con

  31. Slide 31: Medall Acquisition History/Capabilities

    MEDALL ACQUISITION HISTORY/CAPABILITIES Proven Track Record of Acquisitions • 24 acquisitions closed since 2009 • Consummated at lower acquisition multiples than listed Industry peers • Sophisticated integration capabilities Post - Merger Value Creation Source: Medall data 1 Indian financial year is

  32. Slide 32: Medall: Potential Acquisition Targets

    MEDALL: POTENTIAL ACQUISITION TARGETS Target Code Revenue 2 INR Million EBITDA 2 INR Million D1KER11 480 120 D2TEL7 300 75 D1CHN11 300 75 D1ROTN4 300 75 D1ROTN5 300 75 D2TEL8 200 50 D1ROTN6 200 50 D2NAS7 700 35 D2NAS8 120 30 D1CHN17 60 27 Total 2,960 612 Tracking 118 potential acquisition targets 1

  33. Slide 33: Select Publicly Traded Comparables

    SELECT PUBLICLY TRADED COMPARABLES FINANCIAL YEAR CALENDARIZED TO APRIL 1 - MARCH 31 Source: Bloomberg as July 31, 2018. Note: n.m. - Not Meaningful. 1. Revenue growth is for FY19 (financial year from April 1 - March 31, 2019) for Indian companies and for FY18 for US and EM companie s (financial yea

  34. Slide 34: Attractive Valuation: Relative to US Peers

    Select US Peers With High Anticipated EBITDA Growth ATTRACTIVE VALUATION: RELATIVE TO US PEERS 34 6 20% 3% 7% Target Neo Biorad Revenue Growth (FY18 - 19) Source: Bloomberg as July 31, 2018. Note: Revenue and EBITDA growth for US companies represent financial year Jan1 - Dec 31, 2018 and Indian comp

  35. Slide 35: Attractive Valuation: Relative to Indian Peers

    Indian Diagnostics Peers ATTRACTIVE VALUATION: RELATIVE TO INDIAN PEERS 35 6 20% 17% 23% Target Dr Lal Thyrocare Revenue Growth (FY18 - 19) Source: Bloomberg as July 31, 2018. Note: Financials for Indian companies represent financial year ending March 31; Current represents financial year from April

  36. Slide 36: IPO Performance of Indian Diagnostics Peers

    IPO PERFORMANCE OF INDIAN DIAGNOSTICS PEERS 36 6 Source: Bloomberg 1. Performance on listing measured as Day 1 Closing Price over IPO price Note: Medall Purchase EV is ~3x total size of Thyrocare IPO IPO Date Dec 23, 2015 May 09, 2016 EV/EBITDA at IPO 20.6x 24.7x Performance on listing 1 49.8% 38.6%

  37. Slide 37: Appendix

    APPENDIX

  38. Slide 38: Comparative Healthcare Industry Structures

    COMPARATIVE HEALTHCARE INDUSTRY STRUCTURES 1. World Bank 2. Statista, UK Office of National Statistics, India Brand Equity Foundation 3. Centre for Medicare and Medicare services 4. Organisation for Economic Co - operation and Development Market Size • 2016 Healthcare Spending/GDP 1 • 2014 - 2015 Gr

  39. Slide 39: Indian Diagnostics Overview

    INDIAN DIAGNOSTICS OVERVIEW 39 $4.0 vs $5.6 billion Hospital vs Standalone Market $4 - $5 Cost Of Average Pathology Test 56% vs 44% Pathology vs Radiology Revenues $9.6 billion Total Diagnostics Market Size, 2018 25% Growth Rate of Preventative & Wellness Testing Source: Goldman Sachs, Diagnostics a

  40. Slide 40: EBITDA Reconciliation

    EBITDA RECONCILIATION 40 Source: Medall data Audited as per Indian Accounting Standard 1. Presented using exchange rate of $1 to INR 68.4 for the sake of illustration INR, Million USD, Million 1 FY16 - 17 FY17 - 18 FY16 - 17 FY17 - 18 Net Income (48) 273 (0.7) 4.0 Minority Income 1 3 0.0 0.0 Defined

Constellation Alpha Capital — SPAC Merger (August 2018) on 6ix